Video

Dr. Eggermont on the Impact of Adjuvant Anti-PD-L1 Agents in Melanoma

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of adjuvant anti–PD-L1 agents on the treatment landscape of melanoma.

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of adjuvant anti—PD-L1 agents on the treatment landscape of melanoma.

In a study presented at the 2018 AACR Annual Meeting, adjuvant pembrolizumab (Keytruda) reduced the risk of recurrence or death by 43% in patients with resected, high-risk stage III melanoma. The EORTC 1325-MG/KEYNOTE-054 trial randomized patients to 200 mg of pembrolizumab (n = 514) or placebo (n = 505) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxicity.

These results, paired with the FDA approval of nivolumab (Opdivo) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease, has completely changed this setting, says Eggermont. The previously favored ipilimumab (Yervoy) is likely to be replaced with 2 efficacious PD-1 inhibitors, Eggermont concludes.

<<< 2018 AACR Annual Meeting

Related Videos
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School